Home merck
 

Keywords :   


Tag: merck

Merck BRD blog provides updates on disease management

2015-01-12 20:30:57| Beef

If you haven’t visited the Merck Animal Health BRD Report blog, now’s a good time to log in and catch up on the latest thinking on bovine respiratory disease management. read more

Tags: blog management updates disease

 

Merck seeks new OK for cancer drug, reorganization on track

2015-01-12 20:17:01| Biotech - Topix.net

Drugmaker Merck & Co. is ratcheting up its race with rival Bristol-Myers Squibb for leadership in the hot new field of immuno-oncology.

Tags: on track drug cancer

 
 

Merck Provides Update on Strategic Actions to Transform the Company and Build a Platform for Sustained Future Growth at the 33rd Annual J.P. Morgan Healthcare Conference

2015-01-12 13:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KEYTRUDA, First FDA-Approved Anti-PD-1 Therapy, Filed and Launched Within Five Months Company Expects to Submit sBLA for KEYTRUDA in Mid-Year 2015 for Advanced Non-Small Cell Lung Cancer NDA Submission for Hepatitis C Combination Regimen, Grazoprevir/Elbasvir (MK-5172/MK-8742), Planned for First Half of 2015 Seven New Products were Approved in 2014 Company Announced Acquisition of Cubist, Acquired Idenix and Divested its Consumer Care Business Targeted Cost Savings are on Track to be Realized by the End of 2015 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today will report on the ongoing execution of its multi-year, strategic initiative to sharpen its commercial and research and development (R&D) focus, redesign its operating model and reduce its cost base. In October 2013, Merck launched its global initiative to transform the company into a more competitive and innovative company and to build a platform for sustained future growth. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036Steven Cragle, 908-740-1801orInvestors:Justin Holko, 908-740-1879Joe Romanelli, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the company future update

 

Merck to Present at the 33rd Annual J.P. Morgan Healthcare Conference

2015-01-09 14:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, Mercks chairman and chief executive officer, is scheduled to present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 12, 2015 at 4:00 p.m. PST (7:00 p.m. EST). Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at http://www.merck.com/investors/events-and-presentations/home.html. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: present annual conference morgan

 

Merck to Hold Fourth-Quarter and Full-Year 2014 Sales and Earnings Conference Call on February 4

2015-01-05 14:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2014 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Wednesday, Feb. 4. During the call, company executives will provide an overview of Mercks performance for the quarter and full year. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036Steven Cragle, 908-740-1801orInvestors:Justin Holko, 908-740-1879Joe Romanelli, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: on february call sales

 

Sites : [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] next »